Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, announced inducement grants to seven new employees on July 2, 2025. The awards include stock options for 3,500 shares to one employee and restricted stock units (RSUs) for 12,300 shares to seven employees.
The stock options have a 10-year term with a four-year vesting schedule, starting at 25% after the first year, followed by quarterly installments. The options' exercise price is set at $23.21 per share. The RSUs vest annually in four equal installments beginning July 1, 2026. All awards require continued employment with Pacira.
Pacira BioSciences (Nasdaq: PCRX), leader nelle terapie per il dolore non oppioidi, ha annunciato il 2 luglio 2025 l'assegnazione di premi di incentivo a sette nuovi dipendenti. Gli incentivi comprendono opzioni su azioni per 3.500 titoli a un dipendente e unit脿 di azioni vincolate (RSU) per 12.300 titoli a sette dipendenti.
Le opzioni su azioni hanno una durata di 10 anni con un piano di maturazione quadriennale, che prevede il 25% dopo il primo anno, seguito da rate trimestrali. Il prezzo di esercizio delle opzioni 猫 fissato a 23,21$ per azione. Le RSU maturano annualmente in quattro rate uguali a partire dal 1掳 luglio 2026. Tutti i premi richiedono la continuazione dell'impiego presso Pacira.
Pacira BioSciences (Nasdaq: PCRX), l铆der en terapias para el dolor sin opioides, anunci贸 el 2 de julio de 2025 la concesi贸n de incentivos a siete nuevos empleados. Los premios incluyen opciones sobre acciones por 3.500 t铆tulos para un empleado y unidades de acciones restringidas (RSU) por 12.300 t铆tulos para siete empleados.
Las opciones sobre acciones tienen un plazo de 10 a帽os con un calendario de adquisici贸n de derechos de cuatro a帽os, comenzando con un 25% tras el primer a帽o, seguido de pagos trimestrales. El precio de ejercicio de las opciones est谩 fijado en $23,21 por acci贸n. Las RSU se adquieren anualmente en cuatro cuotas iguales a partir del 1 de julio de 2026. Todos los premios requieren continuar el empleo en Pacira.
Pacira BioSciences (雮橃姢雼�: PCRX)電� 牍勲鞎届劚 韱奠 旃橂 攵勳暭鞚� 靹犽憪欤检瀽搿滌劀 2025雲� 7鞗� 2鞚� 7氇呾潣 鞁犾瀰 歆侅洂鞐愱矊 鞚胳劶韹半笇 氤挫儊鞚� 氚滍憸頄堨姷雼堧嫟. 靾橃儊 雮挫毄鞐愲姅 頃� 歆侅洂鞐愱矊 3,500欤� 欤检嫕毵れ垬靹犿儩甓�瓿� 7氇� 歆侅洂鞐愱矊 12,300欤� 鞝滍暅 欤检嫕 雼渼(RSU)臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
欤检嫕毵れ垬靹犿儩甓岇潃 10雲� 旮瓣皠鞚措┌, 4雲勱皠 甓岆Μ 旆摑 鞚检爼鞚� 鞝侅毄霅橃柎 觳� 頃� 頉� 25%臧� 旆摑霅橁碃 鞚错泟 攵勱赴氤勲 雮橂垊鞏挫雼堧嫟. 鞓奠厴鞚� 頄夓偓臧�瓴╈潃 欤茧嫻 23.21雼煬搿� 靹れ爼霅橃柎 鞛堨姷雼堧嫟. RSU電� 2026雲� 7鞗� 1鞚茧秬韯� 4雲勳棎 瓯胳硱 鞐瓣皠 霃欖澕頃� 4須� 攵勴暊搿� 甓岆Μ 旆摑霅╇媹雼�. 氇摖 氤挫儊鞚� Pacira鞐愳劀鞚� 瓿勳啀 攴茧臧� 臁瓣贝鞛呺媹雼�.
Pacira BioSciences (Nasdaq : PCRX), un leader des th茅rapies contre la douleur non opio茂des, a annonc茅 le 2 juillet 2025 l鈥檃ttribution de primes d鈥檌ncitation 脿 sept nouveaux employ茅s. Les r茅compenses comprennent des options d鈥檃chat d鈥檃ctions pour 3 500 actions 脿 un employ茅 et des unit茅s d鈥檃ctions restreintes (RSU) pour 12 300 actions 脿 sept employ茅s.
Les options d鈥檃chat ont une dur茅e de 10 ans avec un calendrier d鈥檃cquisition des droits sur quatre ans, d茅butant 脿 25 % apr猫s la premi猫re ann茅e, puis par versements trimestriels. Le prix d鈥檈xercice des options est fix茅 脿 23,21 $ par action. Les RSU sont acquises annuellement en quatre versements 茅gaux 脿 partir du 1er juillet 2026. Toutes les r茅compenses n茅cessitent la poursuite de l鈥檈mploi chez Pacira.
Pacira BioSciences (Nasdaq: PCRX), ein f眉hrendes Unternehmen f眉r nicht-opioide Schmerztherapien, gab am 2. Juli 2025 die Gew盲hrung von Anreizpr盲mien an sieben neue Mitarbeiter bekannt. Die Auszeichnungen umfassen Aktienoptionen f眉r 3.500 Aktien an einen Mitarbeiter und Restricted Stock Units (RSUs) f眉r 12.300 Aktien an sieben Mitarbeiter.
Die Aktienoptionen haben eine Laufzeit von 10 Jahren mit einem vierj盲hrigen Vesting-Plan, beginnend mit 25 % nach dem ersten Jahr, gefolgt von viertelj盲hrlichen Raten. Der Aus眉bungspreis der Optionen ist auf 23,21 $ pro Aktie festgelegt. Die RSUs werden j盲hrlich in vier gleichen Raten ab dem 1. Juli 2026 眉bertragen. Alle Auszeichnungen erfordern eine fortgesetzte Besch盲ftigung bei Pacira.
- Company demonstrates ability to attract talent with equity compensation
- Structured vesting schedule helps retain employees over 4-year period
- Potential dilution from 15,800 new shares
- Additional stock-based compensation expense will impact financial statements
BRISBANE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on July 2, 2025 to seven new employees under Pacira鈥檚 Amended and Restated 2014 Inducement Plan (the 鈥淚nducement Plan鈥�) as a material inducement to each employee鈥檚 entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the 鈥淐ommittee鈥�) without stockholder approval.
One employee received stock options to purchase an aggregate of 3,500 shares of Pacira common stock and seven employees received restricted stock units for an aggregate of 12,300 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient鈥檚 first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of
Vesting of the equity awards is subject to the employee鈥檚 continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL庐 (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA庐 (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera庐潞, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201 (enekinragene inzadenovec), a novel, locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.
Investor Contact: Susan Mesco, (973) 451-4030 [email protected] Media Contact: Sara Marino, (973) 370-5430 [email protected]
FAQ
What inducement grants did Pacira BioSciences (PCRX) announce on July 3, 2025?
What is the vesting schedule for Pacira's (PCRX) new stock options?
When do Pacira's (PCRX) newly granted RSUs begin vesting?
What was the exercise price for Pacira's (PCRX) inducement stock options?
